Hasil Pencarian  ::  Simpan CSV :: Kembali

"Glaukoma adalah penyebab kebutaan yang ireversibel dengan prevalensi yang kian meningkat. Sebagian besar penderita glaukoma juga mengalami mata kering. Mata kering merupakan efek samping tersering akibat obat tetes mata topikal berpengawet benzalkonium klorida pada penderita glaukoma. Selain itu, glaukoma dan mata kering memiliki faktor risiko yang sama, yaitu usia lanjut dan jenis kelamin wanita. Mata kering pada penderita glaukoma perlu ditangani segera karena menyebabkan ketidaknyamanan, mengurangi kepatuhan berobat, dan menurunkan tingkat keberhasilan terapi. Penanganan mata kering pada penderita glaukoma dapat dilakukan melalui penggunaan obat tanpa pengawet benzalkonium klorida, kombinasi dengan obat yang tidak mengandung pengawet untuk mengurangi paparan, pemberian air mata buatan, dan pembedahan untuk mengurangi kebutuhan obat anti glaukoma topikal.

---

Glaucoma is a common cause of irreversible blindness with increasing prevalence. Some of glaucoma patients will also experience dry eye. Dry eye is the most frequent side effects related to benzalkonium chloride (BAC)-containing eye drop used for glaucoma patients. In addition, glaucoma and dry eye have shared risk factors that are old age and female. Dry eye among glaucoma patients needs to be treated promptly as it produces discomfort, reduces patients? compliance and decreases success rate of glaucoma therapy. Dry eye symptoms can be treated by applying preservative-free eye drop, giving combination with preservative-free eye drop to reduce BAC exposure, prescribing artificial tear and conducting surgery to minimize or eliminate the need of topical medication."

"Tujuan:Membandingkan perubahan,nilai puncak dan rata-rata tekanan intra okular (TIO) pada pasien glaukoma primer sudut terbuka (GPSTa) yang terkontrol menggunakan travoprost 0,004 %dengantimolol hydrogel 0,1% padauji provokes iminum air. Metode: ujieksperimental tersamar tunggal pada 42 pasien GPSTa yang dibagi secara acak menjadi dua kelompok. Kelompok yang mendapatkan pengobatan dengan Travoprost 0,004% dengan frekuensi sekali/hari, selanjutnya dibandingkan dengan yang mendapatkan Timolol hydrogel 0,1% sekali/hari. Pemeriksaan TIO dilakukan pada evaluasi minggu ke-empat pasca terapi, meliputi TIO baseline sebelum uji provokasi minum air, TIO menit ke-15, 30, 45, 60, 75, 90, 105, dan 120 pasca uji provokasi minum air. Hasil:Setelah terapi selama empat minggu, TIO baseline sebelum uji provokasi minum air tidak berbeda bermakna antara kelompok travoprost 0,004% dibandingkan dengan timolol hydrogel 0,1% (p=0,28; uji T tidak berpasangan). Nilai TIO minimal dan maksimal pasca uji provokasi minum air secara signifikan lebih rendah pada kelompok travoprost 0,004% dibandingkan dengan timolol hydrogel 0,1% (p=0,04; p=0,01, uji T tidak berpasangan). Nilai mean TIO pada kelompok travoprost juga didapatkan lebih rendah dibandingkan dengan timolol hydrogel 0,1% (p=0,02, uji T tidak berpasangan). Tidak didapatkan perbedaan bermakna antara fluktuasi TIO kelompok travoprost 0,004% dengan timolol hydrogel 0,1% (p=0,15, uji Mann Whitney). Kesimpulan: Travoprost 0,004% lebihbaikdalammempertahankanTIO dibandingkan dengan Timolol Hydrogel 0,1% pada uji Provokasi Minum Air.

---

Objective: To evaluate the intraocular pressure (IOP) profile after water drinking test (WDT) in primary open angle glaucoma (POAG) patients who had already treated with travoprost 0,004% eye drop versus timolol hydrogel 0,1%.

Methods: A single-blind experimental study. Fourty two POAG patients were randomly assigned to receive travoprost 0,004% once daily or timolol hydrogel 0,1% once daily. The IOP profiles were evaluated 4-weeks after treatment, including baseline IOP before WDT, IOP 15-, 30-, 45-, 60-, 75-, 90-, 105-, and 120-minutes after WDT.

Results: At 4-week after treatment, travoprost 0,004% and timolol hydrogel 0,1% had equivalent effect on baseline IOP (p=0,28; unpaired t-test). Minimum and maximum IOP after WDT of travoprost 0,004% group were significantly less than timolol hydrogel 0,1% group (p=0,04; p=0,01; unpaired t-test, respectively). Mean IOP of travoprost 0,004% group was lower than hydrogel 0,1% group as well (p=0,02; unpaired t-test). The IOP fluctuation was not different between two groups (p=0,15; Mann Whitney test).

Conclusion: This study suggests that travoprost 0,004% was more likely to maintain IOP after WDT compared to timolol hydrogel 0,1% treatment."

"[ABSTRAKTujuan: Untuk mengevaluasi pengaruh pemberian suplementasi Mirtogenol terhadap perubahan ketebalan lapisan serabut saraf retina dan lapang pandang pada pasien dengan glaukoma primer sudut terbuka (GPSTa) dengan tekanan intraokular (TIO) terkontrol.Metode: Penelitian ini merupakan penelitian prospektif, acak, tersamar ganda. Empat puluh satu pasien dengan GPSTa dengan TIO ≤ 18 mmHg diacak untuk mendapatkan Mirtogenol atau plasebo. Perubahan ketebalan RNFL dan MD lapang pandang diperiksa sebelum penelitian, 4 minggu serta 8 minggu setelah pemberian obat. Efek samping pengobatan ditanyakan kepada pasien selama penelitian.Hasil: Rerata ketebalan RNFL kelompok Mirtogenol mengalami penurunan sebesar -0.70±1.63 μm dari 87.29±19.39 μm di awal penelitian menjadi 86.58±19.43 μm setelah 8 minggu, namun perubahan yang terjadi tidak bermakna secara statistik (p=0.121). Rerata ketebalan RNFL kelompok plasebo mengalami penurunan sebesar -1.74±1.79 μm dari 97.14±17.19 μm di awal penelitianmenjadi 95.40±18.56 μm setelah 8 minggu, perubahan yang terjadi bermakna secara statistik (p< 0.001). Rerata MD lapang pandang kelompok Mirtogenol mengalami peningkatan 0.542±1.93 dB setelah 8 minggu sedangkan rerata MD lapang pandang kelompok plasebo mengalami penurunan sebesar -0.083±1.36 dB setelah 8 minggu. Namun perubahan rerata MD lapang pandang kedua kelompoktidak bermakna secara statistik (p>0.05). Selama penelitian tidak didapatkan adanya efek samping.Kesimpulan: Mirtogenol dapat mempertahankan ketebalan lapisan serabut saraf retina, dan MD lapang pandang pada pemberian Mirtogenol cenderung meningkat.

---

ABSTRACTObjective: To evaluate the effect of Mirtogenol towards the changes in retinal nerve fiber layer (RNFL) thickness and visual field in patients with primary open angle glaucoma (POAG) with controlled IOP.Methods: This is a prospective, double blind, randomized study. Forty one POAG patients with IOP ≤ 18 mmHg were randomly assigned to receive either Mirtogenol or placebo. Changes in RNFL thickness and mean deviation of visual fields were evaluated before the treatment, as well as 4 weeks and 8 weeks after the treatment. Patients were asked for any side effects during the treatment period.Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63 μm from 87.29±19.39 μm before the treatment to 86.58±19.43 μm after 8 weeks of treatment, however the change was not significant (p=0.121). The average RNFL thickness in the placebo group decreased -1.74±1.79 μm from 97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks of treatment, the change was statistically significant (p< 0.001). The average MD of visual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks oftreatment while the MD of visual field in the placebo group decreased 0.083 ± 1.36 dB after 8 weeks of treatment. Hoewever the changes in MD of visual field was not significant (p>0.05). No side effect was found throughout the study.Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields.;Objective: To evaluate the effect of Mirtogenol towards the changes in retinalnerve fiber layer (RNFL) thickness and visual field in patients with primary openangle glaucoma (POAG) with controlled IOP.Methods: This is a prospective, double blind, randomized study. Forty onePOAG patients with IOP ≤ 18 mmHg were randomly assigned to receive eitherMirtogenol or placebo. Changes in RNFL thickness and mean deviation of visualfields were evaluated before the treatment, as well as 4 weeks and 8 weeks afterthe treatment. Patients were asked for any side effects during the treatment period.Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63μmfrom87.29±19.39μmbeforethetreatmentto86.58±19.43μmafter8weeks of treatment, however the change was not significant (p=0.121). Theaverage RNFL thickness in the placebo group decreased -1.74±1.79 μm from97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks oftreatment, the change was statistically significant (p< 0.001). The average MD ofvisual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks oftreatment while the MD of visual field in the placebo group decreased 0.083±1.36dBafter8weeksoftreatment.HoeweverthechangesinMDofvisualfieldwasnotsignificant(p>0.05).Noside effectwasfound throughoutthestudy.Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields., Objective: To evaluate the effect of Mirtogenol towards the changes in retinalnerve fiber layer (RNFL) thickness and visual field in patients with primary openangle glaucoma (POAG) with controlled IOP.Methods: This is a prospective, double blind, randomized study. Forty onePOAG patients with IOP ≤ 18 mmHg were randomly assigned to receive eitherMirtogenol or placebo. Changes in RNFL thickness and mean deviation of visualfields were evaluated before the treatment, as well as 4 weeks and 8 weeks afterthe treatment. Patients were asked for any side effects during the treatment period.Results: The average RNFL thickness in the Mirtogenol group decreased 0.70±1.63μmfrom87.29±19.39μmbeforethetreatmentto86.58±19.43μmafter8weeks of treatment, however the change was not significant (p=0.121). Theaverage RNFL thickness in the placebo group decreased -1.74±1.79 μm from97.14±17.19 μm before the treatment to 95.40±18.56 μm after 8 weeks oftreatment, the change was statistically significant (p< 0.001). The average MD ofvisual field in the Mirtogenol group increased 0.542±1.93 dB after 8 weeks oftreatment while the MD of visual field in the placebo group decreased 0.083±1.36dBafter8weeksoftreatment.HoeweverthechangesinMDofvisualfieldwasnotsignificant(p>0.05).Noside effectwasfound throughoutthestudy.Conclusions: Mirtogenol seemed to maintain retinal nerve fiber layer thickness and increased mean deviation of visual fields.]"

"Deteksi progresi glaukoma penting untuk menentukan efektivitas terapi, dan inisiasi atau eskalasi terapi glaukoma sering kali bergantung pada penilaian progresi. Meskipun demikian, tingkat kesepakatan (agreement) di antara para ahli dalam mengidentifikasi progresi glaukoma bervariasi antar penelitian. Penelitian ini membandingkan agreement dan waktu interpretasi progresivitas glaukoma oleh dokter spesialis mata menggunakan dua metode: perangkat lunak FORUM® dan printouts hasil pemeriksaan OCT dan Humphrey. Sebanyak 36 sample cases yang masing-masing terdiri dari minimal 3 laporan OCT dan 5 laporan Humphrey dinilai oleh 12 dokter spesialis mata non-glaukoma (observers). Agreement terhadap status progresi glaukoma antara observers dan konsensus spesialis glaukoma dan dinyatakan dalam nilai Kappa. Waktu interpretasi merupakan total waktu yang dibutuhkan oleh observers untuk menilai progresivitas glaukoma pada seluruh kasus (n=36). Tingkat agreement terhadap status progresi glaukoma ketika menggunakan FORUM® dan ketika menggunakan metode konvensional (printouts) sama baik, dengan nilai Kappa rata-rata 0,62±0,16 vs. 0,63±0,22 (p=0,928). Metode FORUM® memiliki waktu interpretasi rata-rata yang lebih singkat dibandingkan dengan metode printouts, namun tidak bermakna secara statistik (29,1±9,5 vs. 38,8±13,6 menit, p=0,055). Studi ini menunjukkan bahwa penilaian progresi glaukoma menggunakan perangkat lunak FORUM® Glaucoma Workplace tidak memiliki keunggulan dibandingkan metode printouts dalam hal agreement terhadap status progresi dan waktu interpretasi.

---

Detecting glaucoma progression is crucial for determining whether current therapy is effective, and the initiation or escalation of glaucoma therapy often depends on progression status. However, the level of agreement among experts in identifying glaucoma progression varies across studies. This study aims to compare the agreement and interpretation time of glaucoma progression assessment using two methods: the FORUM® software and printouts of OCT and Humphrey reports, as assessed by ophthalmologists. A total of 36 sample cases comprising minimum 3 OCT and 5 Humphrey reports were assessed by 12 ophthalmologists. Agreement on glaucoma progression between observers and standard reference was presented as Kappa value. Interpretation time was defined as the total time required by observers to assess glaucoma progression across all sample cases (n=36). The level of agreement on progression status between the observers when they used FORUM® and conventional (printouts) method were both good, with mean Kappa value 0.62±0.16 vs. 0.63±0.22 respectively (p=0.928). The FORUM® method had a shorter mean interpretation time compared to printouts method, but not statistically significant (29.1±9.5 vs. 38.8±13.6 minutes, p=0.055). This study showed that the assessment of glaucoma progression using FORUM® Glaucoma Workplace software has no superiority to printouts method in terms of agreement on progression status and interpretation time."

"Penyakit glaukoma ditandai dengan hilangnya serabut saraf optik dan astrosit. Kehilangan ini dapat diperiksa dengan mengukur ketebalan neuro-retinal rim dan ukuran optic cup sehubungan dengan optic disc. Namun, penentuan glaukoma masih membutuhkan pemeriksaan mata lengkap oleh dokter mata. Beberapa metodologi otomatis berdasarkan transfer learning deep convolutional neural network untuk klasifikasi glaukoma telah dikembangkan. Untuk meningkatkan akurasi dari penelitian sebelumnya, digunakan metode transfer learning dari metode klasifikasi skin cancer. Arsitektur Inception-v3 dan ResNet50 serta pengklasifikasi serial dari kedua arsitektur tersebut dikembangkan untuk klasifikasi glaukoma otomatis menggunakan citra fundus. Selain arsitektur, variasi splitting dataset dengan metode train-test-split validation serta k-fold cross validation dibandingkan untuk mendapatkan nilai akurasi tertinggi. Berdasarkan hasil penelitian, model terbaik yang didapatkan berupa Inception-v3 dengan metode validasi train-valid-test rasio 80:20 dengan akurasi 95%, presisi 96%, sensitivitas 95%, dan skor-f1 95%. Pembagian 80:20 dipilih karena cocok dengan ukuran dataset yang digunakan. Performa model ini lebih baik dari metode yang telah ada sebelumnya, yaitu Xception dengan peningkatan akurasi sebanyak 2%.

---

Glaucoma is characterized by loss of optic nerve fibers and astrocytes. This loss can be checked by measuring the thickness of the neuro-retinal rim and the size of the optic cup in relation to the optic disc. However, the determination of glaucoma still requires a complete eye examination by an ophthalmologist. Several automated methodologies based on transfer learning deep convolutional neural networks for glaucoma classification have been developed. To increase the accuracy of previous research, transfer learning method is used from the skin cancer classification method. The Inception-v3 and ResNet50 architectures also the serial classifiers of the two architectures were developed for automatic glaucoma classification using fundus images. In addition to the architecture, variations of splitting datasets using the train-test-split validation method and k-fold cross validation were compared to get the highest accuracy value. Based on the results of the study, the best model obtained was Inception-v3 with a train-valid-test ratio validation method of 80:20 with 95% accuracy, 96% precision, 95% sensitivity, and 95% f1-score. The 80:20 division was chosen because it matches the size of the dataset used. The performance of this model is better than the previous method, namely Xception with an increase in accuracy of 2%."

"Glaukoma merupakan suatu kelompok neuropati optik progresif yang ditandai dengan kelainan struktural dan fungsi saraf optik. Fungsi penglihatan yang paling terganggu pada penderita glaukoma adalah lapang pandangan. Pemeriksaan perimetri berguna untuk mengidentifikasidan mengukur defek lapang pandangan serta memperkirakan progresivitas glaukoma. Aplikasi perimetri berbasis tablet atau website sangat berguna untuk pemantauan pasien selama pandemi Covid-19 dan dapat digunakan di daerah terpencil dengan keterbatasan alat Humphrey Field Analyzer (HFA). Perimetri Melbourne Rapid Fields (MRF) merupakan teknologi baru yang terjangkau, mudah dibawa dan andal, serta dapat memberikan manfaat yang sama dengan perimetri HFA. Tujuan: Menilai kesesuaian hasil perimetri MRF terhadap HFA pada pasien glaukoma derajat sedang– berat dengan tajam penglihatan terganggu. Metode: Penelitian observasional dengan desain potong lintang untuk menilai hubungan tajam penglihatan terhadap kesesuaian hasil perimetri MRF 24-2 dibandingkan dengan HFA 24-2 pada pasien glaukoma derajat sedang-berat. Dilakukan pengelompokan subjek ke dalam dua grup berdasarkan tajam penglihatan. Setiap subjek dilakukan pemeriksaan dengan dua macam alat, urutan pemeriksaan dilakukan randomisasi blok. Pemeriksaan perimetri HFA sebanyak satu kali dan pemeriksaan MRF sebanyak dua kali. Hasil pemeriksaan yang memenuhi kriteria dilakukan analisis komparatif, korelasi, kesesuaian, serta test-retest repeatability. Hasil: Total 64 mata dari 57 subjek terbagi dalam dua kelompok. Durasi pemeriksaan MRF lebih singkat dibanding HFA (265,7 ± 26,6 vs 384,4 ± 46,7, p < 0,001). Tidak terdapat perbadaan bermakna pada indeks reliabilitas kedua alat. MRF menunjukkan korelasi dan kesesuaian yang sangat kuat dan baik dengan HFA (R = 0,931, ICC = 0,957, p < 0,001 pada hasil mean deviation (MD) dan R = 0,941, ICC = 0,974, p < 0,001 pada hasil Visual Field Index (VFI)). Test-retest repeatability MRF menunjukkan korelasi dan kesesuaian yang sangat baik (R = 0,948, ICC = 0,989, p < 0,001 pada hasil MD dan R = 0,946, ICC = 0,989, p < 0,001 pada hasil Visual Capacity (VC)). Tidak didapatkan korelasi antara tajam penglihatan dengan Root Mean Squared Error (RMSE) hasil MRF, p > 0,05. Kesimpulan: Hasil perimetri MRF memiliki korelasi yang sangat kuat dnegan HFA. MRF juga menunjukkan hasil test-retest repeatability yang sebanding dengan HFA.Keakuratan hasil MRF tidak berkorelasi dengan perbedaan tajam penglihatan.

---

Background: Glaucoma is a group of progressive optic neuropathy characterized by structural and functional abnormalities of the optic nerve. The most impaired visual function in glaucoma sufferers is the visual field. Perimetric examination is useful for identifying and measuring visual field defects and predicting the progression of glaucoma. Tablet or website-based perimetry applications are very useful for monitoring patients during the Covid-19 pandemic and can be used in remote areas with limited Humphrey Field Analyzer (HFA) perimetry. Melbourne Rapid Fields (MRF) is a new perimetry technology that is affordable, portable and reliable, also can provide the same benefits as HFA perimetry.

Objective: To assess the agreement of MRF perimetry results with HFA in moderate to severe glaucoma patients with impaired visual acuity.

Methods: Observational study with a cross-sectional design to assess the relationship of visual acuity to the agreement of perimetry MRF 24-2 versus HFA 24-2 in patients with moderate-to-severe glaucoma. Subjects were grouped into two groups based on visual acuity. Each subject was examined with two kinds of perimetry, the order of examination was randomized using block randomization. Participants were tested once on HFA and twice on MRF. Examination results that meet the criteria are analyzed for comparative, correlation, agreement, and test-retest repeatability

Results: A total of 64 eyes from 57 subjects were divided into two groups. MRF examination duration was shorter than HFA (265.7 ± 26.6 vs 384.4 ± 46.7, p < 0.001). There is no significant difference in the reliability index of the two perimetry. MRF showed a very strong and good correlation and agreement with the HFA (R = 0.931, ICC = 0.957, p < 0.001 in the mean deviation (MD) and R = 0.941, ICC = 0.974, p < 0.001 in the results of the Visual Field Index (VFI)). The MRF test-retest repeatability showed a very good correlation and agreement (R = 0.948, ICC = 0.989, p < 0.001 on the MD and R = 0.946, ICC = 0.989, p < 0.001 on the Visual Capacity (VC)). There was no correlation between visual acuity and Root Mean Squared Error (RMSE) MRF, p > 0.05. 

Conclusion: The perimetry results from MRF have a very stong correlation to the HFA outcomes. MRF reveals test-retest repeatability comparable to HFA. The accuracy of MRF results did not correlate with differences in visual acuity."

"[ABSTRAKTujuan : Mengevaluasi ada tidaknya perbedaan kualitas air mata pada penderita glaukoma yangmengalami mata kering antara yang diberi tetes mata sodium hialuronat 0,1% mengandung bahanpengawet benzalkonium klorida dan tetes mata sodium hialuronat 0,1% tanpa bahan pengawet.Metode : Penelitian ini merupakan penelitian prospektif terandomisasi. 30 pasien glaukoma yangmengalami mata kering dirandomisasi ke dalam kedua kelompok. Kelompokpertama,mendapatkan obat tetes mata artificial tear mengandung sodium hialuronat 0,1% denganpengawet benzalkonium klorida, sedangkan kelompok II, mendapatkan obat tetes mata artificialtear mengandung sodium hialuronat 0,1% tanpa pengawet selama 1 bulan. Pemeriksaan Schirmertest, TFBUT, OPI, dan sitologi impresi dilakukan pada kedua kelompok baik sebelum dan sesudah1 bulan penetesan obat tetes mata artificial tear.Results: Nilai median sitologi impresi sel goblet pasca penetesan artificial tear meningkat padakelompok I (118,15-485) dan kelompok II (67.0-200), namun secara statistik tidak ada perbedaanbermakna. Nilai rata ? rata TFBUT pasca penetesan pada kelompok I (14,45±7,85) dan kelompokII (13,91±7,46) meningkat dibandingkan sebelum penetesan, serta secara statitstik memilikiperbedaan yang bermakna. Nilai Schirmer test dan OPI pasca penetesan pada kedua kelompokmengalami peningkatan secara klinis dibandingkan sebelum penetesan, namun tidak terdapatperbedaan bermakna secara statistik.Conclusions : Pemberian artificial tear mengandung sodium hialuronat 0,1% baik denganpengawet maupun tanpa pengawet selama 1 bulan memberikan peningkatan Schirmer test,TFBUT,OPI dan sitologi impresi sel goblet.

---

ABSTRACTObjectives: To evaluate the difference of quality of tears between glaucoma patients sufferingfrom dry eyes treated with 0.1% sodium hyaluronat eyedrops with preservativebenzalconiumchloride and those treated with 0.1% sodium hyaluronat eyedrops withoutpreservative.Methods: This is a randomized prospective study. Subjects were 30 glaucoma patients sufferingfrom dry eyes, whom later randomized into two groups. Group I was treated with artificial tearseye drops, which contained 0.1% sodium hyaluronat and benzalconium chloride preservative,whereas Group II was treated with artificial tears eye drops, which contained 0.1% sodiumhyaluronat without preservative for one-month duration. Before and after the treatment withartificial tears eyedrops, subjects of both groups were tested with Schirmer test, TFBUT, OPI, andimpression cytology.Results: The median of goblet cells in impression cytology after treatment with artificial tears eyedrops increased in group I (118, 15 ? 485) and group II (67, 0 ? 200), even though not statisticallysignificant. Mean TFBUT after treatment was also higher in Group I (14.45±7.85) and Group II(13.91±7.46), yet not statistically significant. Schirmer test and OPI results after treatment showeda clinical improvement in both groups, however no statistic result was found to be significant.Conclusions: Treatment with artifical tears eye drops containing 0.1% sodium hyaluronat with orwithout preservative for one month will improve Schirmer test, TFBUT, OPI, and goblet cellsimpressions cytology result on glaucoma patients suffering from dry eyes.;Objectives: To evaluate the difference of quality of tears between glaucoma patients sufferingfrom dry eyes treated with 0.1% sodium hyaluronat eyedrops with preservativebenzalconiumchloride and those treated with 0.1% sodium hyaluronat eyedrops withoutpreservative.Methods: This is a randomized prospective study. Subjects were 30 glaucoma patients sufferingfrom dry eyes, whom later randomized into two groups. Group I was treated with artificial tearseye drops, which contained 0.1% sodium hyaluronat and benzalconium chloride preservative,whereas Group II was treated with artificial tears eye drops, which contained 0.1% sodiumhyaluronat without preservative for one-month duration. Before and after the treatment withartificial tears eyedrops, subjects of both groups were tested with Schirmer test, TFBUT, OPI, andimpression cytology.Results: The median of goblet cells in impression cytology after treatment with artificial tears eyedrops increased in group I (118, 15 – 485) and group II (67, 0 – 200), even though not statisticallysignificant. Mean TFBUT after treatment was also higher in Group I (14.45±7.85) and Group II(13.91±7.46), yet not statistically significant. Schirmer test and OPI results after treatment showeda clinical improvement in both groups, however no statistic result was found to be significant.Conclusions: Treatment with artifical tears eye drops containing 0.1% sodium hyaluronat with orwithout preservative for one month will improve Schirmer test, TFBUT, OPI, and goblet cellsimpressions cytology result on glaucoma patients suffering from dry eyes., Objectives: To evaluate the difference of quality of tears between glaucoma patients sufferingfrom dry eyes treated with 0.1% sodium hyaluronat eyedrops with preservativebenzalconiumchloride and those treated with 0.1% sodium hyaluronat eyedrops withoutpreservative.Methods: This is a randomized prospective study. Subjects were 30 glaucoma patients sufferingfrom dry eyes, whom later randomized into two groups. Group I was treated with artificial tearseye drops, which contained 0.1% sodium hyaluronat and benzalconium chloride preservative,whereas Group II was treated with artificial tears eye drops, which contained 0.1% sodiumhyaluronat without preservative for one-month duration. Before and after the treatment withartificial tears eyedrops, subjects of both groups were tested with Schirmer test, TFBUT, OPI, andimpression cytology.Results: The median of goblet cells in impression cytology after treatment with artificial tears eyedrops increased in group I (118, 15 – 485) and group II (67, 0 – 200), even though not statisticallysignificant. Mean TFBUT after treatment was also higher in Group I (14.45±7.85) and Group II(13.91±7.46), yet not statistically significant. Schirmer test and OPI results after treatment showeda clinical improvement in both groups, however no statistic result was found to be significant.Conclusions: Treatment with artifical tears eye drops containing 0.1% sodium hyaluronat with orwithout preservative for one month will improve Schirmer test, TFBUT, OPI, and goblet cellsimpressions cytology result on glaucoma patients suffering from dry eyes.]"

"Tujuan tulisan ini adalah untuk membandingkan penurunan tekanan intraokuler (TIO) setelah pemberian obat tetes mata Trovoprost 0,004% dengan setelah pemberian timolol 0,5% pada glaukoma primer sudut tertutup kronik. Penelitian prospektif yang dilakukan dari April 2005 sampai Juli 2005 di Departemen Mata Rumah Sakit Cipto Mangunkitsumo (RSCM) Jakarta pada pasien glaukoma primer sudut tertutup kronik. Subjek dibagi secara acak menjadi 2 grup: grup pertama diberi tetes mata Travoprost 0,004% sekali sehari, dan grup ke dua diberi timolol 0,5% dim kali sehari. Dua minggu sesudah pengobatan dengan obat yang pertama, obat diganti dengan obat yang kedua. Tekanan intraokuler dicatat sebelum pengobatan dimulai, pada hari 1, hari 7 dan hari 14. Masa wash out terlaksanakan selama tiga minggu sebelum terapi awal dan setelah dilakukkan cross over. Enam belas pasien (32 mata) memenuhi kriteria inklusi dan diikutsertakan pada penelitian ini. Sebelum terapi, TIO pada grup Travoprost sebesar 25.38 ± 3,01 sedangkan pada grup timolol sebesar 25,88 ± 2,55 mmHg (p=0,354). Pada hari ke 7 pengobatan, TIO untuk masing-masing sebesar 16,75 ± 1,92 dan 21,25 +_ 3,09 (p=0,00l). Sedangkan pada hari ke 14 pengobatan, TIO untuk masing-masing grup sebesar 13,94 ±_ 2,02 dan 19,25 ± 2,18 (p=000). Dengan demikian Travoprost secara statistik bermakna menurunkan TIO lebih cepat dan besar dari pada timolol (p<0.05). Telex mala Travoprost 0,004% menurunkan tekanan intraokuler lebih cepai dan lebih besar daripada teles mata limolol 0,5%. (Med J Indones 2006; 15:242-5).

---

The objective of this study is to compare the reduction of intraocular pressure (IOP) after instillation of Travoprost compared with timolol in chronic primary angle-closure glaucoma. A prospective randomized, crossover study was conducted from April 2005 to July 2005 at Department of Ophthalmology, National Central General. Hospital (RSCM) Jakarta on subjects with chronic primary angle-closure glaucoma. Subjects were randomly divided into 2 groups: those taking Tmvoprost once daily and those taking timolol twice daily. Two weeks after treatment with the first drug, the second drug was substituted. Intraocular pressure was recorded before therapy, at day 1, day 7, and day 14. There was a wash out period of three weeks prior to initial treatment and after the cross over. Sixteen subjects (32 eyes) met the inclusion criteria and were included in this study. The mean baseline (OP in the Travoprost group was 25.38 ±3.01 mmHg, while in the timolol group it was 25.88 ±2.55 mmHg (p=0.354). At dav 7, the IOP were consecutively 16.75 ± 1.92 mmHg and 21.25 ± 3.09 mmHg (p=0.00i) and at day 14 IOP were 13.94 + 2.02 mmHg and 19.25 + 2.18 mmHg (p=000). This showed that Travoprost decreased the IOP faster and greater than timolol. The mean baseline IOP was 25.38 ± 3.01 mmHg was decreased to 11.44 ± 1.90 mmHg with Travoprost. In the timolol group, the mean baseline IOP of 25.88 ± 2.55 mmHg was decreased to 6.63 ± 2.25 mmHg. Statistically, Travoprost significantly reduced the IOP faster and greater than timolol "

"Latar belakang: Glaukoma merupakan kondisi rusaknya saraf optik yang mengakibatkan penderitanya mengalami penurunan lapang pandang dan ketajaman penglihatan. Saat ini, glaukoma masih menjadi penyebab utama kebutaan ireversibel di dunia. Kondisi menurunnya kemampuan penglihatan hingga kebutaan pada pasien glaukoma berdampak dalam fungsinya dalam menjalani aktivitas sehari-hari sehingga kualitas hidup penderita dapat menurun. Glaukoma yang tidak diketahui penyebab pastinya disebut sebagai glaukoma primer, yang kemudian dibagi menjadi dua subtipe yaitu sudut terbuka dan sudut tertutup berdasarkan kondisi anatomis dan patofisiologi. Perbedaan perjalanan penyakit pada kedua subtipe glaukoma primer tersebut diyakini dapat memengaruhi kualitas hidup penderitanya secara berbeda. Dengan demikian, penelitian ini dilakukan untuk membandingkan kualitas hidup antara pasien glaukoma primer sudut terbuka dengan sudut tertutup.Metode: Penelitian ini merupakan studi cross-sectional. Pasien glaukoma primer sudut terbuka dan sudut tertutup yang aktif berobat di RSCM Kirana hingga Juli 2022 diundang untuk berpartisipasi. Penilaian kualitas hidup dilaksanakan dengan The 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) berbahasa Indonesia yang telah divalidasi.Hasil: Terdapat 70 subjek dari tiap kelompok. Terdapat perbedaan yang signifikan (p = 0.012) pada skor rerata kualitas hidup antar kelompok, dengan glaukoma primer sudut tertutup (72.38) lebih tinggi dibanding sudut terbuka (65.53).Kesimpulan: Pasien glaukoma primer sudut tertutup memiliki kualitas hidup yang lebih baik dibanding pasien glaukoma primer sudut terbuka.

---

Introduction: Glaucoma is a condition where the optical nerves are damaged, resulting in reduced visual fields and decreased visual acuity. Glaucoma is the leading cause of irreversible blindness in the world. Visual impairments in glaucoma cause the patients inconveniences in doing their daily activities and thus could decrease their degree of quality-of-life. Primary glaucoma is idiopathic, meaning that there is no definite cause of the disease. Primary glaucoma could be differentiated into 2 subtypes according to the anatomic and pathophysiologic conditions: open angle glaucoma and angle-closure glaucoma. The disease progression of each subtype is different and thus each subtype may affect the quality-of-life of the patients in different manners. This study is aimed to compare the quality-of-life between patients with primary open angle glaucoma (POAG) and primary angle-closure glaucoma (PACG).

Method: Cross-sectional study was conducted. The patients of POAG and PACG that were actively seeking treatment in RSCM Kirana until July 2022 are invited to participate. Quality-of-life of the patients were evaluated using the validated Bahasa Indonesia version of 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25).

Result: Each of the groups consisted of 70 subjects. This study shows significant difference (p = 0.012) of the quality-of-life scores between the groups, with PACG scored higher (72.38) than POAG (65.53).

Conclusion: PACG patients have better quality of life compared to POAG patients."

"Latar belakang: Glaukoma merupakan penyakit kronik pada mata yang menjadi penyebab kebutaan kedua setelah katarak di Indonesia. Saat ini, terdapat sejumlah 427.091 penduduk Indonesia yang menjalani rawat jalan terkait glaukoma. Pada tingkat global, glaukoma sudut terbuka merupakan penyebab kebutaan pertama. Pengobatan farmakologis jangka panjang merupakan terapi utama untuk mencegah progresivitas glaukoma yang memerlukan kepatuhan penggunaan obat oleh pasien. Tujuan: Memberikan gambaran mengenai tingkat kepatuhan penggunaan obat pasien glaukoma sudut terbuka di RSCM Kirana sebagai pusat rujukan nasional, disertai pengaruh dukungan pengasuh atau keluarga terhadap derajat kepatuhan tersebut. Metode: Studi dilaksanakan secara potong lintang dengan teknik pengambilan sampel consecutive. Sampel terpilih sejumlah 96 orang merupakan pasien tergolong kriteria inklusi dari RSCM Kirana. Sampel diwawancarai secara daring dengan pertanyaan bersumber dari kuesioner adaptasi Morisky Medication Adherence Scale dan Duke UNC-Functional Social Support Questionnaire. Hasil: Distribusi derajat dukungan pengasuh atau keluarga dari 96 responden adalah 29.2% beroleh dukungan rendah, 51.04% dukungan sedang, dan 19.8% dukungan tinggi. Sementara distribusi derajat kepatuhan penggunaan obat adalah 50% beroleh kepatuhan rendah, 32.3% kepatuhan sedang, dan 17.7% kepatuhan tinggi. Nilai p (p=0.822) menunjukkan bahwa tidak ada pengaruh signifikan antara derajat dukungan pengasuh atau keluarga terhadap derajat kepatuhan penggunaan obat pasien glaukoma sudut terbuka di RSCM Kirana. Simpulan: Derajat dukungan pengasuh atau keluarga tidak memiliki pengaruh signifikan dengan derajat kepatuhan penggunaan obat pasien glaukoma sudut terbuka (p>0.05) dan diperlukan penelitian lebih lanjut untuk mengatasi keterbatasan studi

---

Background: Glaucoma is a chronic eye disease which causes blindness second to cataracts in Indonesia. Currently, there are 427,091 Indonesians who undergo outpatient care related to glaucoma. Open-angle glaucoma is the leading cause of blindness globally. Long-term pharmacological treatment is suggested as the main therapy to prevent disease progression therefore requires adherence. Objective: To provide an overview of the level of medication adherence in open-angle glaucoma outpatients at RSCM Kirana along with the effect of family or caregiver support upon it. Methods: The study design was cross-sectional with a consecutive sampling technique. The selected sample of 96 people were RSCM Kirana open-angle glaucoma outpatients who fulfilled the inclusion criteria requirements. The sample was interviewed online with questions adapted from the Morisky Medication Adherence Scale and Duke UNC-Functional Social Support Questionnaire. Results: The distribution regarding the degree of caregiver or family support out of 96 respondents were 29.2% experienced low support, 51.04% had moderate support, and 19.8% had high support. On the other hand, the distribution of medication adherence degree were 50% had low adherence, 32.3% had moderate adherence, and 17.7% had high adherence. The p-value (p = 0.822) indicates the degree of family or caregiver support has no significant effect on the degree of adherence to medication outcome in open-angle glaucoma patients at RSCM Kirana. Conclusions: The degree of family or caregiver support does not significantly affect the degree of adherence to medication use in open-angle glaucoma patients (p> 0.05). Further research is needed to overcome the recent study limitations

"